The BetaShares DRUG ETF provides investors with exposure to leading global healthcare companies, hedged into Australian dollars.
A Best ETFs No Rating rating is a fund rating our analysts apply to funds, LICs, mFunds, or ETFs that represents a ‘pending’ or ‘not yet researched’ status for the fund/ETF.
Please note, our rating methodology, research cycle, and process are currently being updated and will soon include full analyst ETF notes, reports, interviews, research, and ratings on select Australian ETFs and funds.
Be sure to subscribe to our mailing list or take our free ETF course while you wait for the updated features. If you’re a fund manager looking to get your fund independently rated by our team, please get in contact.
This ETF invests in well-known global healthcare companies like Johnson & Johnson, Novartis and Glaxosmithkline. This ETF could be a solution for investors looking for targeted exposure to the global healthcare sector.
DRUG could be used by investors looking for a tactical exposure to global healthcare companies, while reducing currency risk through hedging strategies.
The Best ETFs technical analysis chart pack shows the 12-month share price movements, Stochastic bands and traded volume (for both up and down days). This chart uses end-of-day data, so it’s for illustrative purposes only.
*The warnings on this page are applied by our ETF research team. Please know that these warnings are based on quantitative metrics and our internal methodology. These risks are not exhaustive and therefore they should not be relied upon. Always read the PDS of the function and speak to your financial adviser before acting on this information.
Right now, there are 200+ ETFs on the ASX. Then there are index funds. Hundreds of managed funds. LICs. REITs. And everything in between. Wouldn’t it be nice to make ONE investment and build the strong Core of your portfolio — with just one click?
Rask’s lead ETF research analyst and investing team have identified our #1 ETF for 2021 and beyond. Our analyst team has put together a full research report and a step-by-step investment guide to buying this ETF.